European Cannabis Company Sanity Group Raises $44.2 Million


Sanity Group Closes $44.2M Series A

Largest European Cannabis Funding Round to Date

Berlin, June 15, 2021 – Berlin-based cannabis start-up Sanity Group announced today it has closed a $44.2M USD Series A financing round with new investment led by Swiss venture capital firm Redalpine along with US-based Navy Capital and SOJE Capital. GMPVC also participated in the round.

This represents the largest round of cannabis funding in Europe to date and brings total investment in Sanity Group to $73M USD.

An expanding position as a leading cannabis company in Europe

Sanity Group aims to improve people’s quality of life through the use of cannabinoids. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products.

The new capital will be used primarily to further expand the Group’s medical division in Europe. Funds will also be used for the build out of EU-GMP-compliant research and production facility new Frankfurt am Main for the entire Group, which will serve both the medical and the wellbeing areas of the Sanity Group in the future, and to expand Sanity Group’s consumer goods business. Sanity Group currently employs 90 employees in Europe including cannabis experts, physicians, pharmacists and biologists.

A round of this magnitude shows that cannabis is increasingly moving into the mainstream of investor awareness, and represents an important milestone in our business expansion on our way to becoming Europe’s leading cannabis company.

Finn Age Hänsel, Founder and Managing Director of Sanity Group

We are very pleased about the trust placed in us by new and existing investors. Our thanks go not only to our new partners, but also to those who have been by our side for a long time and support us on our journey.

Previous investors include HV Capital, TQ Ventures, Atlantic Food Labs, Cherry Ventures, Bitburger Ventures and SevenVentures. In addition, Sanity Group has attracted prominent celebrity angels including music producers, Scooter Braun and actress Alyssa Milano

“Our goal is to leverage the full potential of the cannabis plant and to research and harness the various cannabinoids. We are always on the lookout for partners who can not only support us financially in our endeavors, but above all are a good strategic fit for us. Redalpine’s investments in the life science and medical sector as well as Navy Capital with cannabis portfolio companies in the healthcare and consumer-goods sector ideally complement our existing investor setup and cover the entire range of our business in the health, life science and consumer-goods sector,” adds Sanity Group co-founder and Managing Director Fabian Friede, who founded the company in 2018 together with Finn Hänsel with the aim of providing people in Europe with newly developed cannabinoid-based medicines and health products.

The European cannabis market faces exciting developments in the coming months. Compared to the North American market, Europe is now where we were in the U.S. about four years ago. We want to bring our expertise and experience to the table.

Sean Stiefel, CEO at Navy Capital

For our first investment in Europe, it was important for us to find a team that understands the market and has real industry experts in its ranks. The Sanity Group team particularly impressed us with their expertise and clear approach.

About Sanity Group

Sanity Group has set itself the goal of improving people’s quality of life through the sensible use of cannabinoids in Europe. In addition to pharmaceuticals, the focus is also on cannabinoid-based wellbeing and cosmetic products. At the same time, Sanity Group is also working and researching new medical products, innovative dosage forms and technological products and services for the further development of the infrastructure. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 90 people: at the headquarters in Berlin and the research site near Frankfurt am Main. The Sanity Group brands are Vayamed (pharmaceuticals), VAAY (CBD products) and This Place (functional cosmetics). More information at

About Redalpine

Redalpine is a leading European early stage venture capital investor focused on disruptive innovation and with a broad sector investment strategy from health-tech to ICT startups. Redalpine’s diverse team supports the 70+ portfolio companies not only with financial investment but also with its in-house operational and subject matter expertise and extensive international network. Redalpine’s ambition is to help talented entrepreneurs turn their visions into reality and scale their businesses into international success stories.

About Navy Capital

Navy Capital’s research-oriented, fundamentally-driven investment process focuses on identifying attractive opportunities within the Consumer, Healthcare, Technology and Agriculture sectors. Navy Capital invests in publicly traded and private companies that will gain market share over time in their respective verticals.

Original press release

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter